SINTX 2025 Highlights

January 7, 2026

𝗖𝗹𝗼𝘀𝗶𝗻𝗴 𝗼𝘂𝘁 𝘁𝗵𝗲 𝘆𝗲𝗮𝗿 𝘄𝗶𝘁𝗵 𝗴𝗿𝗮𝘁𝗶𝘁𝘂𝗱𝗲. As we look back at 2025, we’re thankful for the progress our team and partners helped drive this year. We advanced our ceramic science, expanded our IP, and pushed our foot and ankle strategy forward in meaningful ways.

Some of the milestones we’re grateful for:
✅ 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆: New capital, a major patent issuance, and tighter focus after divesting our Technology Assessment and Transfer subsidiary.
✅ 𝗠𝗮𝗿𝗰𝗵: Two leadership updates and a published study reinforcing silicon nitride’s performance in cervical spine fusion.
✅ 𝗔𝗽𝗿𝗶𝗹: Strengthened our board to support the next phase of growth.
✅ 𝗠𝗮𝘆: A strategic shift toward medical device commercialization and new IP expanding into agribiotech applications.
✅ 𝗝𝘂𝗻𝗲: A refreshed strategic vision and the acquisition of the SiNAPTIC® Surgical assets, expanding into the foot and ankle market.
✅ 𝗝𝘂𝗹𝘆: Submission of the 510(k) for our silicon nitride foot and ankle devices.
✅ 𝗔𝘂𝗴𝘂𝘀𝘁: Business realignment, leadership expansion, and continued portfolio development.
✅ 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿: A landmark antiviral study, a key patent allowance, successful warrant exercises, and participation in the H.C. Wainwright Global Investment Conference.
✅ 𝗢𝗰𝘁𝗼𝗯𝗲𝗿: Multiple patent allowances strengthening our antipathogenic and infection-prevention platform, plus FDA clearance for the SiNAPTIC® Foot & Ankle Implant System.
✅ 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿: Launch of OsseoSculpt™ and a strong third-quarter update highlighting efficiency gains and strategic momentum, plus attended the North American Spine Society Annual Meeting (NASS).
✅ 𝗗𝗲𝗰𝗲𝗺𝗯𝗲𝗿: Presented at the Sidoti Investor Conference, engaging with investors and sharing our strategy and progress.

Thank you to everyone who contributed this year – partners, customers, investors, and colleagues. Your support and collaboration made this progress possible.

Wishing you a safe night and a meaningful start to the new year.